Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03534323 |
|
Recruitment Status :
Recruiting
First Posted : May 23, 2018
Last Update Posted : January 9, 2024
|
Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Secura Bio, Inc.
Information provided by (Responsible Party):
Matthew S. Davids, MD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | July 1, 2024 |
| Estimated Study Completion Date : | July 1, 2026 |